Difference between revisions of "Venlafaxine-mianserine"
From Psychiatrienet
(Created page with '{{Drugswitch | from = venlafaxine | to = mianserine | stop = * '''Day 0:''' gradually reduce dosage of duloxetine to a maximum of 75 mg/day. * '''Day 1:''' reduce a dosage o...') |
|||
Line 7: | Line 7: | ||
| start = | | start = | ||
* '''Day 1:''' simultaneously start administration of mianserine in a dosage of 30 mg/day. | * '''Day 1:''' simultaneously start administration of mianserine in a dosage of 30 mg/day. | ||
− | * '''Day 8:''' stop administration of venlafaxine and continue administration of mianserine only. If necessary, increase dosage of mianserine to 40-60 mg/day. | + | * '''Day 8:''' stop administration of venlafaxine and continue administration of mianserine only. If necessary, increase the dosage of mianserine to 40-60 mg/day. |
| info = | | info = | ||
* Venlafaxine is a weak inhibitor of CYP2D6, which metabolizes mianserine. }} | * Venlafaxine is a weak inhibitor of CYP2D6, which metabolizes mianserine. }} |
Revision as of 19:35, 5 May 2009
| ||||||||||||||||||||||
|
Switch medication from venlafaxine to mianserine.[1] [2]
- Day 0: gradually reduce dosage of duloxetine to a maximum of 75 mg/day.
- Day 1: reduce a dosage of venlafaxine from 75 mg/day to 37,5 mg/day.
- Day 1: simultaneously start administration of mianserine in a dosage of 30 mg/day.
- Day 8: stop administration of venlafaxine and continue administration of mianserine only. If necessary, increase the dosage of mianserine to 40-60 mg/day.
- Venlafaxine is a weak inhibitor of CYP2D6, which metabolizes mianserine.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.